Buenos Aires - Delayed Quote ARS
AstraZeneca PLC (AZN.BA)
42,150.00
+1,600.00
+(3.95%)
As of 12:25:13 PM GMT-3. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | -- | -- | -- | -- |
| Avg. Estimate | 0 | 0 | 0 | 0 |
| Low Estimate | 0 | 0 | 0 | 0 |
| High Estimate | 0 | 0 | 0 | 0 |
| Year Ago EPS | -- | -- | -- | -- |
Revenue Estimate
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 9 | 8 | 24 | 24 |
| Avg. Estimate | 13.71B | 14.03B | 57.44B | 60.95B |
| Low Estimate | 13.34B | 13.67B | 54.76B | 55.89B |
| High Estimate | 14.02B | 14.79B | 59.62B | 66.44B |
| Year Ago Sales | 12.68B | 12.94B | 54.07B | 57.44B |
| Sales Growth (year/est) | 8.16% | 8.46% | 6.22% | 6.11% |
EPS Trend
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | 0 | 0 | 0 | 0 |
| 7 Days Ago | 0 | 0 | 0 | 0 |
| 30 Days Ago | 0 | 0 | 0 | 0 |
| 60 Days Ago | 0 | 0 | 0 | 0 |
| 90 Days Ago | 0 | 0 | 0 | 0 |
EPS Revisions
| Currency in USD | Current Qtr. (Mar 2025) | Next Qtr. (Jun 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| AZN.BA | -- | -- | -- | -- |
| S&P 500 | 6.94% | 4.52% | 8.32% | 14.18% |
Related Tickers
MRK.BA Merck & Co., Inc.
18,900.00
+1.34%
AMGN.BA Amgen Inc.
11,000.00
+0.69%
PFE.BA Pfizer Inc.
6,900.00
+4.23%
JNJ.BA Johnson & Johnson
12,450.00
+1.63%
BAYRY Bayer Aktiengesellschaft
6.44
+2.71%
RHHBY Roche Holding AG
39.65
+1.38%
NVS Novartis AG
110.89
+0.69%
GSK GSK plc
37.32
+0.78%
AMGN Amgen Inc.
280.00
+0.76%
ABBV AbbVie Inc.
179.60
+1.44%